All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
How will the results of the phase III ASCEND trial change treatment practice of R/R CLL?
Featured:
Paolo GhiaDuring ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Paolo Ghia from University Vita-Salute San Raffaele, Milan, IT, about how the results of the phase III ASCEND trial might change treatment practice of relapsed/refractory chronic lymphocytic leukemia (CLL).
Paolo Ghia discusses how the multicenter, international study compared a classic chemotherapy treatment with a chemotherapy-free treatment, and with a novel BTK inhibitor. He mentions how, for the first time, two chemotherapy-free treatments were compared.
How will the results of the phase III ASCEND trial change treatment practice of R/R CLL?
Your opinion matters
What types of support services or resources do you think would best facilitate the safe implementation of the BrECADD regimen in clinical practice?